Core Viewpoint - The company, HAPO Pharmaceuticals-B (02142), has launched its first fully human AI HCAb model driven by the Hu-mAtrIx™ AI platform, aiming to revolutionize the development of biopharmaceuticals through advanced AI capabilities [1] Group 1: Company Developments - HAPO Pharmaceuticals experienced a stock increase of over 4%, with a current price of 13.49 HKD and a trading volume of 52.54 million HKD [1] - The company successfully held the "Zhiyao HAPO Huichuang Xingchen" global R&D day event in Shanghai on October 28, where the new AI-driven model was officially announced [1] - The AI HCAb model is based on proprietary Harbour Mice® platform data and integrates a fine-tuned large language model (LLM) for sequence generation, along with high-precision AI classification and drugability prediction models [1] Group 2: Industry Implications - The AI HCAb model is expected to accelerate the application of fully human HCAb in next-generation therapeutic areas, including multispecific antibodies, XDC, in vivo CAR-T, and inhaled or oral macromolecular drugs [1] - The platform aims to reshape the landscape of biopharmaceutical development by creating a closed-loop process that combines AI design, intelligent screening, and wet lab validation [1] - HAPO Pharmaceuticals is leveraging AI capabilities and HCAb technology to expedite the implementation of innovative therapies and identify unmet clinical needs through data-driven predictive processes [1]
港股异动 | 和铂医药-B(02142)涨超4% 发布首个全人源HCAb生成模型 加速新一代疗法落地